Cargando…
Use of the CytoSorb adsorption device in MDMA intoxication: a first-in-man application and in vitro study
BACKGROUND: 3,4-Methylenedioxymethamphetamine (MDMA, “ecstasy”) abuse is frequent, and overdosing might cause severe and eventually lethal multi-organ failure. To date, there is no causal therapy of MDMA intoxication and removal of MDMA from the circulation might be a reasonable measure to prevent a...
Autores principales: | Lang, Corinna N., Sommer, Michaela J., Neukamm, Merja A., Staudacher, Dawid L., Supady, Alexander, Bode, Christoph, Duerschmied, Daniel, Lother, Achim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295925/ https://www.ncbi.nlm.nih.gov/pubmed/32542550 http://dx.doi.org/10.1186/s40635-020-00313-3 |
Ejemplares similares
-
CytoSorb removes MDMA in vitro, but is it an effective therapy in vivo?
por: Honore, Patrick M., et al.
Publicado: (2020) -
Does adjunctive hemoadsorption with CytoSorb affect survival of COVID-19 patients on ECMO? Authors' response
por: Supady, Alexander, et al.
Publicado: (2021) -
CytoSorb-friend or foe!!
por: Pattnaik, Saroj Kumar, et al.
Publicado: (2015) -
On the Use of Hemadsorption with CytoSorb in Patients with Septic Shock. Comment on Kogelmann et al. First Evaluation of a New Dynamic Scoring System Intended to Support Prescription of Adjuvant CytoSorb Hemoadsorption Therapy in Patients with Septic Shock. J. Clin. Med. 2021, 10, 2939
por: Supady, Alexander, et al.
Publicado: (2022) -
Comment on: Extracorporeal hemoadsorption in critically ill COVID‑19 patients on VV ECMO: the CytoSorb therapy in COVID‑19 (CTC) registry
por: Supady, A., et al.
Publicado: (2023)